NeuroMab™ Anti-CD40 BBB Shuttle Antibody(NRZP-1022-ZP3818)

Figure 1 is a graph showing the results of an ELISA assay demonstrating that APX005 selectively binds CD40 but not other TNFR family members.

Figure 2 is a graph showing the results of an ELISA assay demonstrating that APX005 blocks the binding of CD40L to CD40.

Figure 3 is a graph showing that APX005 is not internalized after binding to CD40 positive cells.

Figure 4 is a graph showing APX005-mediated ADCC of CD40 positive Ramos (Figure 8A) and Daudi (Figure 8B) tumor cells.

Figure 5 is a graph showing the in vitro inhibition of Ramos tumor cell proliferation by APX005 Group A without Fc cross-linking; Group B with Fc cross-linking.

Figure 6 is a bar graph showing that APX005 induces DC activation.

Figure 7 shows that APX005 binds human and monkey CD40 but not mouse CD40.

Figure 8 is a graph showing that APX005 inhibits tumor growth in the Ramos model. Figure 12B is a bar graph showing serum human IgG levels in mice on day 34, two days after the last dose.

Figure 9 is a graph showing inhibition of rituximab pretreatment and resistant tumors in a mouse model.

Figure 10 is a graph showing that APX005 inhibits tumor growth in the Raji mouse model.

Figure 11 is a graph showing the potent anti-tumor activity of APX005 against human multiple myeloma in the IM-9 xenograft model.